Related Experiment Videos
Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C
1Second Department of Internal Medicine, Tottori University Faculty of Medicine, Japan.
Hepatology (Baltimore, Md.)
|August 1, 1995
Summary
Interferon alfa (IFN-alpha) treatment significantly reduces hepatic fibrosis markers in chronic hepatitis C patients. This antifibrotic effect is sustained long-term, potentially preventing cirrhosis progression.
Area of Science:
- Hepatology
- Virology
- Biochemistry
Background:
- Chronic hepatitis C leads to hepatic extracellular matrix deposition and fibrosis.
- Interferon alfa (IFN-alpha) is a treatment for chronic hepatitis C.
- Assessing IFN-alpha's impact on fibrogenesis is crucial for understanding long-term outcomes.
Purpose of the Study:
- To evaluate the effect of interferon alfa (IFN-alpha) on hepatic extracellular matrix in chronic hepatitis C.
- To investigate changes in serum N-terminal propeptide of type III procollagen (PIIINP) during and after IFN-alpha therapy.
Main Methods:
- A study involving 178 treated and 45 non-treated patients with chronic hepatitis C.
- Serum PIIINP levels were measured before, during, and after a 4-month IFN-alpha treatment course.
- Serum transaminase levels were also monitored for comparison.
Main Results:
- Serum PIIINP levels were significantly higher in nonresponders compared to responders pre-treatment.
- IFN-alpha treatment led to a significant decrease in serum PIIINP levels, sustained for 12 months post-treatment.
- The decrease in PIIINP was more pronounced in patients with elevated baseline levels and correlated better with initial levels than transaminase changes.
Conclusions:
- IFN-alpha treatment induces long-term suppression of active fibrogenesis in chronic hepatitis C.
- This antifibrotic effect is independent of antiviral and anti-necroinflammatory actions.
- IFN-alpha therapy may prevent the progression of chronic hepatitis C to cirrhosis.